Aside from being late, the Novavax option is less promising than its competition. There is no evidence it elicits a useful killer T-cell (CD8+ cell) response to date, which several other vaccines do. It only gives rise to antibodies that we know of. https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1.full.pdf">https://www.medrxiv.org/content/1...
Another disadvantage is that Novavax is not yet in ANY large-scale clinical trial. They only began recruiting for their phase 2 clinical trial today, and it& #39;s TINY, with only about 10% of the trial subjects the competition now has. https://clinicaltrials.gov/ct2/show/NCT04533399?term=novavax&recrs=adf&draw=2&rank=2">https://clinicaltrials.gov/ct2/show/...
I& #39;m afraid. The decision to buy Novavax, but not more proven vaccines, very strongly suggests the govt acted too slowly to secure the most promising products, and is now grasping for something, ANYTHING, that is still available. Canadians should not expect this to end well.
You can follow @profamirattaran.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: